未登录

B

Becky Pennington

School of Medicine and Population Health

H指数:16

被引数:1,181

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Caring for and Caring about in Economic Evaluation: Modelling the Family and Caregiving Effects

经济评估中的“关怀”与“关注”：对家庭和照护效应的建模

PharmacoEconomics

IF4.6

2025-11-010

OA

Challenges in Modelling the Cost Effectiveness of Pharmacotherapies for Obesity

肥胖药物疗法成本效益建模的挑战

PharmacoEconomics

IF4.6

2025-07-280

OAAI

Modelling Informal Carers' Health-Related Quality of Life: Challenges for Economic Evaluation

APPLIED HEALTH ECONOMICS AND HEALTH POLICY

IF3.3

2023-11-102

OAAI

Systematic Review of Cost-Utility Analyses That Have Included Carer and Family Member Health-Related Quality of Life

VALUE IN HEALTH

IF6

2022-09-0120

OAAI

Carers’ Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations

Pharmacoeconomics

IF4.6

2022-07-120

OAAI

How health inequalities accumulate and combine to affect treatment value: A distributional cost-effectiveness analysis of smoking cessation interventions (vol 265, 113339, 2020)

健康不平等如何累积并结合以影响治疗价值: 戒烟干预措施的分布成本效益分析 (265卷，113339，2020)

SOCIAL SCIENCE & MEDICINE

IF5

2021-07-010

OAAI

A Review of the Psychometric Performance of Selected Child and Adolescent Preference-Based Measures Used to Produce Utilities for Child and Adolescent Health

VALUE IN HEALTH

IF6

2021-03-0134

OAAI

How health inequalities accumulate and combine to affect treatment value: A distributional cost-effectiveness analysis of smoking cessation interventions

健康不平等如何累积并结合以影响治疗价值: 戒烟干预措施的分布成本效益分析

SOCIAL SCIENCE & MEDICINE

IF5

2020-11-018

OAAI

A Review of the Methods Used to Generate Utility Values in NICE Technology Assessments for Children and Adolescents

VALUE IN HEALTH

IF6

2020-07-0131

OAAI

Evaluation of Intervention Impact on Health Inequality for Resource Allocation

资源配置对健康不平等的干预效果评价

MEDICAL DECISION MAKING

IF2.3

2019-02-2819

OAAI

The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals

Pharmacoeconomics

IF4.6

2018-08-090

PREAI

The cost-effectiveness of public health interventions examined by NICE from 2011 to 2016

NICE 2011年2016年检查的公共卫生干预措施的成本效益

JOURNAL OF PUBLIC HEALTH

IF3.1

2017-09-1827

OAAI

Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results

VALUE IN HEALTH

IF6

2014-12-0128

OAAI

WHICH METRIC TO CHOOSE FOR INDIRECT COMPARISON OF TREATMENTS WHEN MULTIPLE COMPARISONS ARE FEASIBLE: LUBIPROSTONE VERSUS PRUCALOPRIDE IN CHRONIC CONSTIPATION

VALUE IN HEALTH

IF6

2014-11-010

OAAI

LUBIPROSTONE IN CHRONIC IDIOPATHIC CONSTIPATION: A COST-EFFECTIVENESS ANALYSIS

VALUE IN HEALTH

IF6

2014-11-011

OAAI

Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death

HEALTH AND QUALITY OF LIFE OUTCOMES

IF3.4

2014-09-1051

OAAI

THE INFLUENCE OF HAQ UTILITY MAPPING ALGORITHMS ON THE COST-EFFECTIVENESS OF SECOND LINE BIOLOGICS FOR TREATMENT OF RHEUMATOID ARTHRITIS

VALUE IN HEALTH

IF6

2013-11-010

OAAI

SELECTIVE INTERNAL RADIOTHERAPY (SIRT) USING RESINYTTRIUM-90 MICROSPHERES FOR CHEMOTHERAPY-REFRACTORY METASTATIC COLORECTAL CANCER: A UK COST-EFFECTIVENESS ANALYSIS

VALUE IN HEALTH

IF6

2013-11-013

OAAI

MODELLING THE COST-EFFECTIVENESS OF FIRST LINE BIOLOGICS FOR RHEUMATOID ARTHRITIS IN IRELAND

VALUE IN HEALTH

IF6

2013-11-010

OAAI

A COMPARISON OF METHODOLOGIES FOR ESTIMATING SURVIVAL IN PATIENTS TREATED WITH SECOND-GENERATION TYROSINE-KINASE INHIBITORS (TKIS) FOR CHRONIC MYELOID LEUKAEMIA (CML)

VALUE IN HEALTH

IF6

2013-11-010

OAAI